Tight control of MEK-ERK activation is essential in regulating proliferation, survival, and cytokine production of CD34+-derived neutrophil progenitors

Blood

Volumn 114, Issue 16, 2009, Pages 3402-3412

  Geest, Christian R ^a   Buitenhuis, Miranda ^a   Groot Koerkamp, Marian J A ^a   Holstege, Frank C P ^a   Vellenga, Edo ^b   Coffer, Paul J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CD34 ANTIGEN; CHEMOKINE; CYTOKINE; GROWTH FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; 1,3 BUTADIENE DERIVATIVE; ENZYME INHIBITOR; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NITRILE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NEUTROPHIL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL EXPANSION; BIOSYNTHESIS; DNA MICROARRAY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GRANULOCYTE PRECURSOR; METABOLISM; MUTATION; PHYSIOLOGY;

ANTIGENS, CD34; APOPTOSIS; BUTADIENES; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GRANULOCYTE PRECURSOR CELLS; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; MUTATION; NEUTROPHILS; NITRILES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 70350727161     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2008-08-175141     Document Type: Article

References (60)

1. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene. 2007; 26(47):6724-6737.
2. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol. 1999; 11(2):211-218. (Pubitemid 29164036)
3. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600): 1911-1912. (Pubitemid 35425238)
4. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410(6824):37-40. (Pubitemid 32225829)
5. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol. 1999;19(4):2435-2444.
6. Chang CI, Xu B, Akella R, et al. Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol Cell. 2002;9(6):1241-1249. (Pubitemid 34722303)
7. Tanoue T, Adachi M, Moriguchi T, et al. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol. 2000;2(2):110-116. (Pubitemid 30785922)
8. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263-1284.
9. Boulton TG, Nye SH, Robbins DJ, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 1991;65(4):663-675.
10. Pagès G, Lenormand P, L'Allemain G, et al. Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A. 1993;90(18):8319-8323. (Pubitemid 23277659)
11. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007; 26(22):3100-3112.
12. Peus D, Vasa RA, Beyerle A, et al. UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes. J Invest Dermatol. 1999;112(5):751-756. (Pubitemid 29220718)
13. Ferrell JE Jr. MAP kinases in mitogenesis and development. Curr Top Dev Biol. 1996;33:1-60.
14. Bhat NR, Zhang P. Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: role of extracellular signal-regulated kinase in hydrogen peroxide-induced cell death. J Neurochem. 1999;72(1):112-119. (Pubitemid 29013884)
15. Stevenson MA, Pollock SS, Coleman CN, et al. X-irradiation, phorbol esters, and H2O2 stimulate mitogen-activated protein kinase activity in NIH-3T3 cells through the formation of reactive oxygen intermediates. Cancer Res. 1994;54(1):12-15.
16. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49-139. (Pubitemid 28193546)
17. Chen Z, Gibson TB, Robinson F, et al. MAP kinases. Chem Rev. 2001;101(8):2449-2476.
18. Pagès G, Guérin S, Grall D, et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science. 1999;286(5443):1374-1377. (Pubitemid 129516242)
19. Saba-El-Leil MK, Vella FDJ, Vernay B, et al. An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep. 2003;4(10):964-968. (Pubitemid 37407464)
20. Hatano N, Mori Y, Oh-hora M, et al. Essential role for ERK2 mitogen-activated protein kinase in placental development. Genes Cells. 2003;8(11):847-856. (Pubitemid 37428014)
21. Yao Y, Li W, Wu J, et al. Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation. Proc Natl Acad Sci U S A. 2003;100(22):12759-12764. (Pubitemid 37339972)
22. Roovers K, Assoian RK. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays. 2000;22(9):818-826. (Pubitemid 30681834)
23. Chambard J, Lefloch R, Pouysségur J, et al. ERK implication in cell cycle regulation. Biochim Biophys Acta. 2007;1773(8):1299-1310. (Pubitemid 47125974)
24. Traverse S, Gomez N, Paterson H, et al. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J. 1992;288(Pt 2):351-355.
25. Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science. 1999; 286(5445):1738-1741. (Pubitemid 129515881)
26. Di Cristo G, Berardi N, Cancedda L, et al. Requirement of ERK activation for visual cortical plasticity. Science. 2001;292(5525):2337-2340. (Pubitemid 32568057)
27. Crompton T, Gilmour KC, Owen MJ. The MAP kinase pathway controls differentiation from double-negative to double-positive thymocyte. Cell. 1996;86(2):243-251. (Pubitemid 26286107)
28. Racke FK, Lewandowska K, Goueli S, et al. Sustained activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells. J Biol Chem. 1997;2729(37): 23366-23370. (Pubitemid 27392477)
29. Matsuzaki T, Aisaki KI, Yamamura Y, et al. Induction of erythroid differentiation by inhibition of Ras/ERK pathway in a friend murine leukemia cell line. Oncogene. 2000;19(12):1500-1508. (Pubitemid 30175671)
30. Hsu C, Kikuchi K, Kondo M. Activation of mitogen-activated protein kinase kinase (MEK)/ extracellular signal regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment. Blood. 2007;110(5):1420-1428. (Pubitemid 47443956)
31. Ricciardi MR, McQueen T, Chism D, et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia. 2005;19(9):1543-1549. (Pubitemid 43090397)
32. Kornblau SM, Womble M, Qiu YH, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006;108(7):2358-2365. (Pubitemid 44497520)
33. Giarratana M, Kobari L, Lapillonne H, et al. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Nat Biotechnol. 2005;23(1):69-74. (Pubitemid 41724627)
34. de Jager W, Prakken BJ, Bijlsma JWJ, et al. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods. 2005;300(1-2):124-135.
35. de Jager W, te Velthuis H, Prakken BJ, et al. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2003;10(1):133-139.
36. Buitenhuis M, van Deutekom HWM, Verhagen LP, et al. Differential regulation of granulopoiesis by the basic helix-loop-helix transcriptional inhibitors Id1 and Id2. Blood. 2005;105(11):4272-4281. (Pubitemid 40720773)
37. Blalock WL, Pearce M, Steelman LS, et al. A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. Oncogene. 2000;19(4):526-536. (Pubitemid 30099366)
38. Sherr CJ. Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians. 1995;107(2):181-186.
39. Lavoie JN, L'Allemain G, Brunet A, et al. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 1996;271(34):20608-20616. (Pubitemid 26281839)
40. Weber JD, Raben DM, Phillips PJ, et al. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J. 1997;326(Pt 1):61-68.
41. Daksis JI, Lu RY, Facchini LM, et al. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene. 1994;9(12):3635-3645.
42. Seth A, Alvarez E, Gupta S, et al. A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression. J Biol Chem. 1991;266:23521-23524. (Pubitemid 21908826)
43. Burch PM, Yuan Z, Loonen A, et al. An extracellular signal-regulated kinase 1- and 2-dependent program of chromatin trafficking of c-Fos and Fra-1 is required for cyclin D1 expression during cell cycle reentry. Mol Cell Biol. 2004;24(35):4696-4709. (Pubitemid 38668037)
44. Furukawa Y, Kikuchi J, Nakamura M, et al. Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation. Br J Haematol. 2000;110(3):663-673. (Pubitemid 30769268)
45. Zwijsen RM, Wientjens E, Klompmaker R, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88(3):405-415. (Pubitemid 27131382)
46. Jeffrey KL, Camps M, Rommel C, et al. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov. 2007;6(5):391-403. (Pubitemid 46705202)
47. Parry D, Mahony D, Wills K, et al. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol. 1999;19(3):1775-1783. (Pubitemid 29098236)
48. Sewing A, Wiseman B, Lloyd AC, et al. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol. 1997;17(9):5588-5597. (Pubitemid 27357655)
49. Woods D, Parry D, Cherwinski H, et al. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol. 1997;17(9):5598-5611. (Pubitemid 27357656)
50. Tanaka T, Kurokawa M, Ueki K, et al. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol. 1996;16(7):3967-3979. (Pubitemid 26199916)
51. Morgan MA, Dolp O, Reuter CW. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 2001;97(6):1823-1834. (Pubitemid 32217252)
52. Hoyle PE, Moye PW, Steelman LS, et al. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia. 2000;14(4):642-656.
53. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108(6):851-859. (Pubitemid 32880294)
54. Laurence ADJ. Location, movement and survival: the role of chemokines in haematopoiesis and malignancy. Br J Haematol. 2006;132(3):255-267.
55. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol. 2006;79(4):639-651. (Pubitemid 44835596)
56. Griffin JD, Rambaldi A, Vellenga E, et al. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood. 1987;70(4):1218-1221. (Pubitemid 18022408)
57. Sun Y, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003;89(3):462-473. (Pubitemid 36648768)
58. Goldberg-Bittman L, Neumark E, Sagi-Assif O, et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett. 2004;92(1-2):171-178. (Pubitemid 38470065)
59. Tobler A, Moser B, Dewald B, et al. Constitutive expression of interleukin-8 and its receptor in human myeloid and lymphoid leukemia. Blood. 1993;82(8):2517-2525. (Pubitemid 23304277)
60. Corre I, Pineau D, Hermouet S. Interleukin-8: an autocrine/paracrine growth factor for human hematopoietic progenitors acting in synergy with colony stimulating factor-1 to promote monocytemacrophage growth and differentiation. Exp Hematol. 1999;27(1):28-36. (Pubitemid 29123978)